Vulnerability of the nigrostriatal system as detected by transcranial ultrasound

Neurology

Volumn 53, Issue 5, 1999, Pages 1026-1031

  Berg, D ^c   Becker, Georg ^b   Zeiler, B ^c   Tucha, O ^c   Hofmann, E ^c   Preier, M ^c   Benz, P ^c   Jost, W ^a   Reiners, K ^c   Lange, K W ^c  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NONE

Author keywords

MRI; Neuropsychological assessment; Nigrostriatal system; Preclinical impairment; Transcranial ultrasound; 18F Dopa PET

Indexed keywords

DOPA; FLUORINE 18; NEUROPROTECTIVE AGENT;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; FEMALE; FUNCTIONAL DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR PERFORMANCE; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA;

EID: 0033595447     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.5.1026     Document Type: Article

References (38)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
2. Brooks DJ, Luthert P, Gadian D, Marsden CD. Does signalattenuation on high-field T2 weighted MRI of the brain reflect regional cerebral iron deposition? Observations on the relationsship between regional cerebral water proton T2 values and iron levels. J Neurol Neurosurg Psychiatry 1989;52:108-111.
3. Olanow CW. Magnetic resonance imaging in parkinsonism. Neurol Clin 1992;10:405-420.
4. Antonini A, Leenders KL, Meier D, Oertel WH, Boesinger P, Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 1993;43:697-700.
5. Chen JC, Hardy PA, Kucharczyk W, et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington Disease. Am J Neuro Radiol 1993;14:275-281.
6. Ye FQ, Allen PS, Martin WR. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Mov Disord 1996;11:243-249.
7. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998;65:65-71.
8. 18F]-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
9. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Ach Neurol 1990;47:1290-1298.
10. 18F-dopa and positron emission tomography. Neurology 1992;42:1894-1900.
11. Calne DB, Snow BJ. PET imaging in parkinsonism. Adv Neurol 1993;60:484-487.
12. Shinotoh H, Hirayama K, Tateno Y. Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET. Adv Neurol 1993;60:488-493.
13. 18F]-dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
14. Piccini P, Turjanski N, Brooks DJ. PET studies of the striatal dopaminergic system in Parkinson's disease (PD). J Neural Transm Suppl 1995;45:123-131.
15. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
16. 18F-dopa positron emission tomography study. Ann Neurol 1997;41: 222-229.
17. Ishikawa T, Dhawan V, Kazumata K, et al. Coparative nigrostriatal dopaminergic imaging with iodine-123 beta-CIT-FP/ SPECT and fluorine-18 FDOPA/PET. J Nucl Med 1996;37: 1760-1765.
18. Innins RB, Seibyl JP, Scanley BE. Single photon emission computed tomographic imaging demonstrating loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
19. Brooks DJ. Detection of preclinical Parkinson's disease with PET. Geriatrics 1991;46(suppl 1):25-30.
20. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-184.
21. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
22. Hietanen M, Teravainen H, Tsui JK, et al. The pegboard as a measurement of parkinsonian deficits. Neurology 1987; 37(suppl):266. Abstract.
23. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
24. Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press, 1995.
25. Zimmermann P, Fimm B. A computerized neuropsychological assessment of attention deficits. Freiburg, Germany: Institute of Psychology, University of Freiburg, 1989.
26. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114:2095-2122.
27. Lange KW, Paul GM, Naumann M, Gsell W. Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J Neural Transm Suppl 1995;46:423-432.
28. Troster AI, Stalp LD, Paolo AM, Fields JA, Koller WC. Neuropsychological impairment in Parkinson's disease with and without depression. Arch Neurol 1995;52:1164-1169.
29. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in postmortem substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
30. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occuring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
31. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
32. Dexter DT, Sian J, Jenner P, Marsden CD. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv Neurol 1993;60:273-281.
33. Wang X, Manganaro F, Schipper HM. A cellular stress model for the sequestration of redox-active glial iron in the aging and degenerating nervous system. J Neurochem 1995;64: 1868-1877.
34. Golbe LI. The genetics of Parkinson's disease: a reconsideration. Neurology 1990;40(suppl 13):7-14.
35. Forno LS. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 1969;17:557-575.
36. Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
37. Irwin I, Langston JW. Endogenuos toxins as potential etiologic agents in Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson's disease. New York: Marcel Dekker, 1995:153-202.
38. Spencer PS, Butterfield PG. Environmental agents and Parkinson's disease. In: Ellenberg JH Koller WC, Langston JW, eds. Etiology of Parkinson's disease. New York: Marcel Dekker, 1995:319-366.